Beta-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA)

Trial Profile

Beta-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA)

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms Beta-SPECIFIC-4-Patients
  • Sponsors Novartis
  • Most Recent Events

    • 20 Oct 2017 This trial has been completed in Austria (end date: 25 Sep 2017).
    • 17 Oct 2017 This trial has been completed in Belgium (end date: 25 Sep 2017).
    • 10 Oct 2017 This trial has been completed in Hungary. (End date: 2017-09-25).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top